Madan Jagasia | ASH 2018 | Results from the phase II REACH1 trial in patients with GvHD

Madan Jagasia

Dec 3, 2018

Madan Jagasia | ASH 2018 | Results from the phase II REACH1 trial in patients with acute GvHD

Results from the phase II REACH1 trial in patients with GvHD

More about...

Acute graft-versus-host disease ASH 2018 Madan Jagasia REACH1

Editorial Theme | Novel therapies for the treatment of GvHD

Currently, there are only two approved treatments for GvHD: ruxolitinib, indicated for steroid resistant (SR) aGvHD, and ibrutinib, used in patients with cGvHD who have failed one or more...

Feb 19, 2020

Editorial Theme | Novel therapies for the treatment of GvHD

Currently, there are only two approved treatments for GvHD: ruxolitinib, indicated for steroid resistant (SR) aGvHD, and ibrutinib, used in...

Feb 19, 2020

Shernan Holtan | ASH 2018 | Human chorionic gonadotropin and epidermal growth factor in acute GvHD

Human chorionic gonadotropin and epidermal growth factor in acute GvHD

Dec 13, 2018

Shernan Holtan | ASH 2018 | Human chorionic gonadotropin and epidermal growth factor in acute GvHD

Human chorionic gonadotropin and epidermal growth factor in acute GvHD

Dec 13, 2018

Subscribe to get the best content related to GvHD delivered to your inbox every month

First Name

Last Name

I agree to the GvHD Hub Terms & Conditions

The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Madan Jagasia | ASH 2018 | Results from the phase II REACH1 trial in patients with GvHD

Madan Jagasia

Dec 3, 2018

More about...

Related articles

Feb 19, 2020

Feb 19, 2020

Dec 13, 2018

Dec 13, 2018

Newsletter